The Corporation focussed on the biology of healing has this week updated on its Q2 highlights and financial results. Clearly investors’ current focus is on the anticipated launch of Ryplazim™ for plasminogen deficiency. Prometic is responding diligently to all FDA requests in relation to the BLA review and in the latest conference call revealed that it is confident of commercial launch in Q1 and expects to be launch ready before the year end. 48-week clinical data from plasminogen
22 Aug 2017
Prioritising value creation
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Prioritising value creation
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
22 Aug 2017 -
Author:
Derren Nathan -
Pages:
9
The Corporation focussed on the biology of healing has this week updated on its Q2 highlights and financial results. Clearly investors’ current focus is on the anticipated launch of Ryplazim™ for plasminogen deficiency. Prometic is responding diligently to all FDA requests in relation to the BLA review and in the latest conference call revealed that it is confident of commercial launch in Q1 and expects to be launch ready before the year end. 48-week clinical data from plasminogen